GlaxoSmithKline Plc operates as a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. It operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. The Pharmaceuticals business researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines business produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare business markets a range of consumer health products based on scientific innovation. The company was founded on December 6, 1999 and is headquartered in Brentford, the United Kingdom.
Andrew became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined Glaxo in 1985 and held a variety of Sales and Marketing roles in the UK business.
He has worked in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields and has been involved in multiple new product development programmes.
He has also worked in South Africa, The USA and Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board, the Singapore Land Authority and in 2003 he was awarded the Public Service Medal by the Government of Singapore.
In 2003 Andrew was appointed President of GSK Europe, and joined GSK’s Corporate Executive Team. He was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry in the 2012 New Year Honours List.
Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK, where he is currently a member of the Prime Minister’s Business Advisory Group and is the Lead Non-Executive Director for the Department for Business. Andrew is President of the European Federation of Pharmaceutical Industries and Associations (EFPIA), a position he took up on 1 January 2010. He was a Board Member of the INSEAD Business School until January 2012.
Andrew has a Joint Honours BA in Economics from the University of Nottingham.
Simon Dingemans, Chief Financial Officer
Simon became Chief Financial Officer in April 2011 after joining as Chief Financial Designate in January 2011. He is a member of the Board and the Corporate Executive Team. Simon joined GSK from Goldman Sachs where he was a Managing Director and Partner. He has over 25 years experience in investment banking, including most recently as leader of Goldman Sachs’ European M&A business and before that as head of UK Investment Banking.
He joined Goldman Sachs in 1995, becoming Head of UK Investment Banking in 2000 and leader of Goldman Sachs’ European Mergers and Acquisitions business in 2007. During this time, Simon had specific responsibility for many of the largest and most complex transactions that were carried out by Goldman Sachs in Europe, whilst continuing to have responsibility for a broad range of key UK client relationships, with a primary focus on large corporations.
Prior to joining the Company, Simon worked with GSK for over a decade and was closely involved in a number of GSK’s most important financial and strategic projects during that time, including, most recently, the establishment of ViiV Healthcare. His varied experience across a broad range of sectors during his time at Goldman Sachs has also resulted in direct experience of many of the different healthcare sectors and geographies currently served by GSK, including consumer as well as pharmaceutical markets.
After receiving a Masters degree in Geography from Oxford University in 1985, Simon joined S.G. Warburg Group, the investment banking firm which specialised in mergers and acquisitions, becoming one of its youngest directors in 1994.
David Redfern, Chief Strategy Officer
David was appointed Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities, strategic planning and the leadership of the dermatology business. In addition to his current role, he was appointed Chairman of the Board of ViiV Healthcare Ltd. in April 2011. He is a member of the Corporate Executive Team and reports to the CEO.
Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in that region and prior to that Senior Vice President for Central and Eastern Europe. David joined the company in 1994 and held a series of finance roles before becoming Finance Director of the European business from 1999-2002.
David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.